vimarsana.com
Home
Live Updates
Denileukin Diftitox BLA Resubmitted for CTCL After Addressin
Denileukin Diftitox BLA Resubmitted for CTCL After Addressin
Denileukin Diftitox BLA Resubmitted for CTCL After Addressing FDA Concerns
The biologics license application for denileukin diftitox has been resubmitted to the FDA for the treatment of cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
Related Keywords
Japan ,
Davida Litman ,
Citius Pharmaceuticals Inc ,
Citius Pharmaceuticals ,
Prescription Drug User Fee Act ,
News ,
Articles ,
February 2024 ,
Fda ,
Lymphomas ,
Denileukin Diftitox ,
Bla ,
Biologics License Application ,
Ctcl ,
Pdufa ,
Complete Response Letter ,
Lymphir ,